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Abstract
Purpose: To evaluate the outcomes of patients with gastric cancer bleeding who had been treated with palliative radiotherapy with 
haemostatic intent.
Methods and materials: Fifty-two gastric cancer patients aged 52–92 years (median 78 years) with active bleeding or anaemia resulting 
from inoperable gastric cancer were treated with short-course radiotherapy. Responses to radiotherapy treatment were evaluated based on 
the changes of haemoglobin level, number of transfusions received before and after radiotherapy, and overall median survival.
Results: Thirty-nine (75%) patients received single 8 Gy fraction, and 13 (25%) patients received 20 Gy in five daily fractions. The need for 
transfusion was evaluable in 44 patients, and the response rate was 50%, with less requirement for blood transfusions within four weeks 
of radiotherapy. There was also an increase in mean haemoglobin level (0.66 ± 1.12 g/dl, p < 0.01) after radiotherapy in 35 evaluable 
patients. The overall median survival (calculated from last day of treatment to date of death) was 160 days (95% CI of 119–201 days), 
making actuarial 12-month survival 15%. 
Conclusion: Palliative short-course radiotherapy is a reasonably effective treatment that can provide durable palliation of bleeding in 
gastric cancer.
Keywords: bleeding, gastric cancer, haemostasis, palliative, radiotherapy.
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Introduction
Gastric cancer is the fourth most common malignancy in men and the fifth most common malignancy in women globally. It accounts for 
8% of the total number of cases of cancer and 10% of annual deaths from cancer worldwide [1]. The current curative treatment for gastric 
cancer is surgery, but most patients are diagnosed with locally advanced or metastatic disease at presentation. The prognosis of these 
patients is poor, and a five-year survival rate of 10–20% has been reported [2, 3]. 
The local symptoms caused by gastric cancer are pain, obstruction (dysphagia, vomiting), and bleeding (melaena, haematemesis). Overt 
gastrointestinal bleeding from gastric cancer at presentation is uncommon but does occur in up to 10% of patients [4], and this can be a 
very distressing symptom for both patients and their family members. Chronic bleeding from gastric cancer can cause anaemia and subse-
quently fatigue and anorexia. Anaemia can also interfere with symptom control, and control of bleeding is important to improve the quality 
of life in these patients [5]. 
There are several treatment modalities for gastric bleeding, including palliative surgical resection, endoscopic treatment, and radiotherapy, 
but little research into which treatment is the most effective option has been performed.
Gastric cancer bleeding can be relieved by palliative resection; however, only fit patients can undergo surgery, and it is associated with 
significant mortality approaching 10% as well as morbidity in about a third of patients [6–8]. Surgery may provide rapid relief from symptoms, 
but prolongation of survival is noted in only 6% of patients and improvement in the quality of life following palliative resection is unclear [7].
Endoscopic intervention including argon plasma coagulation has been reported to achieve haemostasis in 67% of patients with gastro-
duodenal tumour bleeding [9]; however, this is associated with risk of perforation (5–15%), and the re-bleeding rate is high [9].
Radiotherapy has been used to palliate bleeding from other malignant tumours such as lung, cervical, and bladder cancers [10, 11]. Radia-
tion causes denudation of the intima of the blood vessels supplying the tumour, leading to capillary necrosis and the formation of thrombo-
sis, which blocks the lumen of blood vessels, achieving haemostasis [4]. The response rate to this treatment has been reported to be as 
high as 50–90% [2–4, 12, 13], but the retrospective nature of these reports needs to be taken into account.
Here, we report the results of a single-centre retrospective study on ‘short-course’ radiotherapy to palliate patients with symptomatic locally 
advanced gastric cancer and evaluate its effectiveness in relieving symptoms of bleeding or anaemia. 
Methods and materials
Patients 
Two hundred and ninety-eight consecutive patients who were diagnosed with gastric cancer between May 2001 and December 2010 and 
referred for oncological treatment were analysed retrospectively. The patients regarded as having gastric cancer on endoscopy findings 
and who had a pathological diagnosis of only high-grade dysplasia were included. Furthermore, those patients who presented with gas-
trointestinal bleeding or anaemia and were treated with short-course palliative radiotherapy were eligible for inclusion in this retrospective 
study. The diagnosis of gastrointestinal bleeding was established either by endoscopic findings or from the clinical symptoms of patients 
(melaena or haemetemesis) supported by evidence of a low or falling haemoglobin level. In our region, palliative radiotherapy to the 
stomach alone is generally reserved for patients unfit for other treatment strategies such as chemotherapy or surgery.
The patients’ gender, age, histology, stage, and treatment factors (use of chemotherapy before and after radiation treatment, postradiation 
transfusion and mean haemoglobin level before and after radiotherapy) as well as radiotherapy parameters (field arrangements, total dose, 
dose fractionation regimens) were extracted from the patient records.
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Treatment procedures
All patients with gastrointestinal bleeding received external beam radiotherapy using high-energy (6 or 10 MV) photons from a linear accel-
erator. The patients were treated supine with parallel-opposed pair of anterior/posterior fields, and the radiotherapy was delivered either as 
a single fraction of 8 or 20 Gy in five daily fractions over one week. The 20 Gy treatment in five fractions was usually given to patients with a 
better performance status or those who had dysphagia caused by tumour obstructing the lower oesophagus.
Response assessment
The efficacy of the short-course radiotherapy was evaluated. With reference to previous studies by other groups [2, 4, 12, 13], we defined 
a positive radiotherapy response if
•	 patients	subsequently	required	a	blood	transfusion	but	did	not	need	one	in	the	four	weeks	after	radiotherapy	was	given	(‘transfusion	
group’) or
•	 patients	did	not	require	transfusion	at	all	and	survived	for	three	months	or	more	(‘Non-transfusion	group’).	
We also evaluated the efficacy of the short-course radiotherapy on the basis of improvement in haemoglobin levels in patients after the 
radiotherapy.
The difference between the mean haemoglobin values before and after radiotherapy was therefore reviewed. The mean preradiotherapy 
haemoglobin level was obtained from the blood test results from the day of admission to hospital with gastrointestinal bleeding to the first 
fraction of radiotherapy. Hence the value reflects the underlying disease and effects of transfusion only. The mean postradiotherapy hae-
moglobin level reflects the four-week period starting with the last fraction of radiotherapy. This parameter was used to measure the effect of 
radiotherapy: a decrease from the mean preradiotherapy haemoglobin level was considered to be indicative of re-bleeding.
We were also keen to determine the overall survival of this group of patients, which we calculated from the day the patient received the last 
fraction of radiotherapy.
Statistical analysis
Statistical analyses were carried out with the SPSS (Statistical Package for Social Sciences) version 18. Survival was estimated by the 
Kaplan–Meier method. Univariate analysis with log rank test was performed to study different factors correlating with survival. The alteration 
of haemoglobin levels was analysed with paired t-test; p-values <0.05 were considered to be statistically significant.
Results
Sixty-four of the 298 patients were referred for palliative radiotherapy for haemostatic intent. However, 12 of the 64 patients did not receive 
palliative radiotherapy after the initial consultation either because the oncologist assessed that they were not fit for treatment or there was 
no immediate indication for the treatment. Fifty-two patients received palliative radiotherapy for control of bleeding symptoms of locally 
advanced gastric cancer. The clinical details of these 52 patients are summarised in Table 1. The median age of the patients was 78 years 
(range 52–92 years); they were predominantly male (n = 34, 65%). The median age for the male patients was 76 years (range 52–90 years), 
and the median age for the female patients (n = 18, 35%) was 81 years (range 61–92 years).
Thirty-nine (75%) patients received a single 8 Gy treatment and 13 (25%) patients received 20 Gy in five daily fractions. Two patients were 
subsequently re-treated with palliative radiotherapy (both re-treatments were with an 8 Gy single fraction). One of them received 8 Gy 
single fraction on two occasions for haemostatic intent, and these radiotherapy treatments were given eight months apart. The other patient 
was initially treated with 20 Gy in five fractions for palliation of dysphagia, and further radiotherapy treatment was given one year later for 
haemostatic intent. There were seven (14%) patients treated with systemic chemotherapy before receiving short-course radiotherapy for 
controlling the bleeding symptom, and only three (6%) patients received systemic treatment after palliative radiotherapy for control of the 
disease, as would be expected for an unfit cohort of patients. 
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Table 1. Patients’ demographics.
Number (n) Percentage (%)
Gender
Male 34 65
Female 18 35
Age (years old)
51–60 5 10
61–70 8 15
71–80 19 37
81–90 19 37
> 91 1 2
Disease Status
Stage I 2 4
Stage II 4 8
Stage III 13 25
Stage IV 23 44
Biopsy proven, staging not documented 7 14
Presumed gastric carcinoma, staging not 
documented
3 6
Histology
Poorly differentiated adenocarcinoma 27 52
Mucinous adenocarcinoma 1 2
Signet ring adenocarcinoma 6 12
Carcinoma with neuroendocrine features 3 6
Intestinal type adenocarcinoma 4 8
High-grade dysplasia 2 4
Moderately differentiated adenocarcinoma 7 14
Anaplastic carcinoma 1 2
Squamous cell carcinoma 1 2
Pre-radiotherapy chemotherapy
Yes
No
7
45
14
86
Treatment outcomes
Response to radiotherapy
Eight of the 52 patients had received palliative radiotherapy for haemostasis but did not have any documentation of transfusion data. Hence 
the response to short-course treatment could not be evaluated in these patients. The 44 remaining evaluable patients were categorised into 
two groups in terms of transfusion requirement (Table 2).
Non-transfusion group: Fifteen patients did not receive any transfusion after palliative radiotherapy. One patient died within a week and 
six patients died within a month. The remained eight patients survived beyond three months and did not require transfusion; hence the 
response rate to radiotherapy in this group was 53% (8/15).
Transfusion group: Twenty-nine patients required postradiation transfusion. Of the 29 patients, fifteen (52%) required transfusion within 
four weeks; hence palliative radiotherapy was deemed ineffective. Fourteen of the 29 patients required transfusion at least a month or 
more after radiotherapy. Hence, the ‘response rate’ to radiotherapy was 48% (14 of 29). We also reviewed the number of transfusions that 
patients required until they died (Table 2). Thirteen (45%) of the 29 patients required one transfusion before they died, and the rest required 
multiple transfusions before death. 
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Thus, 22 of 44 patients (50%), that is, 14 from transfusion group and 8 from non-transfusion group, responded to radiotherapy.
Mean haemoglobin difference before and after radiotherapy
Only 35 patients had complete preradiotherapy and postradiotherapy haemoglobin levels recorded, and in these patients, the differences 
in mean values were evaluated. The blood results of the remaining 17 patients were not evaluable due to incomplete documentation. The 
mean haemoglobin value before palliative radiotherapy for these 35 patients was 9.53 g/dl, whereas the mean haemoglobin level after 
radiotherapy treatment was 10.2 g/dl. There was a statistically significant improvement in mean haemoglobin level after radiotherapy com-
pared with the preradiotherapy haemoglobin (p < 0.01, Figure 1). 
Table 2. Number of transfusions required by 44 patients before they died.
Category Number of transfusions 
required
Number of patients 
Non Transfusion group 0 15
Transfusion group
1
2
3
4
7
8
10
13
 4
 5
 4
 1
 1
 1
Total no. of patients 44
8 patients did not have documentation of transfusion, hence were not included 
in this analysis
Figure 1. Differences in mean haemoglobin level before and after palliative radiotherapy in 35 patients. Twenty-six patients had an increase in 
mean haemoglobin level after treatment, whereas nine patients had a fall. The overall increment in mean haemoglobin level was 0.66 ±1.12g/dl 
in 35 patients, p < 0.01.
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Median survival
The overall median survival of patients in this study was 160 days (95% CI of 119–201 days) ranging from 6 days to 1053 days. At the time 
of analysis, four patients were still alive (Figure 2). The median survival of those 12 patients who did not receive palliative radiotherapy 
was 49 days (95% CI of 18–80 days).
The survival rates at 3, 6, and 12 months were 65%, 23%, and 15%, respectively. Univariate analysis on different pretreatment factors 
(stage, histology, radiotherapy dose, etc.) that might have an impact on survival was performed, but as shown in Table 3, no statistically 
significant difference was found.
Figure 2. Kaplan–Meier survival curve of 52 patients receiving palliative radiotherapy. The overall median survival of these patients was  
160 days (95% CI 119–201 days). Four patients were alive and censored at the time of analysis. 
Table 3. Factors that could potentially have an impact on median survival time.
Factors Median survival (days)
p value
Gender
 · Female 137 0.97
 · Male 160  
Disease status
 · Stage I 163
 · Stage II 420
 · Stage III 121 0.73
 · Stage IV 137
 · Biopsy proven gastric carcinoma, no staging documented 160
 · Presumed gastric carcinoma, no staging documented 241
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Table 3. Continued.
Histology   
 · Poorly differentiated adenocarcinoma 161
 · Mucinous adenocarcinoma 276
 · Signet ring adenocarcinoma 168
 · Carcinoma with neuroendocrine features 277 0.068
 · Intestinal type adenocarcinoma 47
 · High grade dysplasia 241
 · Moderately differentiated adenocarcinoma 110
 · Anaplastic carcinoma 171
 · Squamous cell carcinoma 474  
Radiotherapy regimen
 · 8 Gy 142 0.202
 · 20 Gy in 5 fractions 239
Chemotherapy given prior to radiation treatment   
 · Yes 110 0.128
 · No 161  
Chemotherapy given after radiation treatment
 · Yes 289 0.487
 · No 142
Age Group   
 · 51–60 110
 · 61–70 90 0.209
 · 71–80 161
 · 81–90 160
Discussion
There are five retrospective studies in recent years that have described the benefits of using radiotherapy to palliate bleeding in patients 
with unresectable gastric cancer [2–4, 12, 13]. The response rates for controlling bleeding in these studies varied from 50–90%, such wide 
range is due to the difference in the definition of treatment success. The reported overall median survival with palliative radiotherapy varied 
from 3–5.2 months (Table 4). These retrospective studies, however, had relatively small sample sizes of 19–37 patients, and no randomised 
controlled trial to evaluate the efficacy of short-course radiotherapy on the palliation of symptomatic gastric cancer has been published. 
Our study evaluated the outcomes of 52 patients with gastric cancer bleeding treated with radiotherapy in a single regional centre over a 
ten-year period, with the sample size larger than those reported previously [2–4, 12, 13]. Like all retrospective works, the results need to 
be interpreted with caution. It is difficult to obtain retrospective data for each patient in a standard way, and the information on performance 
status or symptom improvement may be hard to obtain in all cases. The strengths of our series are that all patients in our catchment popula-
tion (approximately 400,000) were treated in a single oncology radiotherapy centre by only a few consultants using a similar technique. We 
therefore believe that these results reflect outcomes typical for all-comers within a population rather than subgroups selected for study, for 
example, in clinical trials with specific exclusion criteria. We believe case ascertainment to be high for similar reasons of easy data retrieval 
from the comprehensive and mainly electronic records of one regional Scottish centre.
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The	majority	 (73%)	of	 the	patients	were	elderly	patients	over	70	years	of	age	and	were	unfit	 to	 receive	 radical	 treatment	or	palliative	
systemic treatment. A small number of patients in our study had been diagnosed with early-stage disease (stages I and II) but owing to 
significant co-morbidities were fit neither for surgery nor for palliative chemotherapy; therefore palliative radiotherapy was given for patients 
who were symptomatic with bleeding. As none of our patients received concurrent chemoradiation treatment, and only 14% of patients 
(7 of 52) received chemotherapy prior to radiotherapy, this has provided a useful description of the natural history of patients who are 
treated with radiotherapy alone. Six percent (3 of 52) of these patients received systemic treatment after radiotherapy. The overall median 
survival in our group of 160 days was unlikely to be confounded by the use of other treatments, and this result was similar to the result 
shown by Tey et al [12]. 
Different dose fractionation schedules varying from single 8 Gy to dose of 50 Gy in 25 fractions have been published in previous papers 
[2–4, 12, 13]. Two of the studies suggested the use of higher biological effective dose (BED) of over 39 Gy [2, 3] would provide better local 
control and also survival. Tey et al suggested that there was no statistically significant difference in median survival between lower and 
higher BED, but the result favoured the use of higher dose, which tended to confer longer survival [12]. Our study could lend support to this, 
as the median survival of the 39 patients receiving a single 8 Gy versus the 13 patients treated with 20 Gy in five fractions was 142 versus 
239 days, respectively, p = 0.202 (Table 3); however, this finding is likely be confounded by the selection of patients with better performance 
status for the longer fractionation and by the preferences of the radiotherapist. Assuming alpha/beta (α/β) ratio was 10, the BED in our study 
ranged from 14.4 Gy (8 Gy single fraction) to 28 Gy (20 Gy in five fractions), which was at least 1.5 times less than the dose applied in the 
previous studies [2, 3, 12, 13], although the results appear similar. Our study has shown that the use of lower dose treatment has shown a 
similar median survival compared with higher dose treatment in this, generally unfit, patient cohort.
Previous studies evaluated the response of radiotherapy by reviewing the pre- and postradiotherapy haemoglobin levels and also the 
reduction of transfusion units or amount of transfused blood after radiotherapy [2, 4, 13]. However, it is unclear from these studies at 
what stage and how often after radiotherapy, the haemoglobin level was checked. Lee et al had commented on the challenging aspects 
of assessing the efficacy of radiotherapy [4]. This correctly states that a single haemoglobin level as an end point to evaluate response is 
flawed, as haemoglobin level does not reflect acute gastrointestinal bleeding directly, and because the level of haemoglobin varies with 
gender and also comorbidity. Therefore, Lee et al. had suggested the use of mean value of haemoglobin level and mean value of reduc-
tion in transfusion units required postradiotherapy for a period of three months. A mean haemoglobin level is more likely to reflect the true 
effect of radiotherapy.
We evaluated the response to treatment by calculating the mean value of haemoglobin levels preradiotherapy and postradiotherapy. There 
was a statistically significant increase in the level of haemoglobin after radiotherapy. This finding was comparable with the results reported 
in the previous studies (Table 4), which showed an increase in the level of postradiotherapy haemoglobin although the values did not return 
to the reference range in all cases. The likely explanation was that anaemia persisted because of underlying disease and comorbidity of 
patients, even though radiotherapy has achieved haemostatic effects.
Most studies deemed radiotherapy treatment effective if patients did not require transfusion within four weeks or more after radiotherapy 
[2, 4, 13] in which the cutoff point of four weeks seems arbitrary. For the purpose of comparison of response to short-course radiotherapy, 
we adopted the similar approach. We assessed the response of short-course radiotherapy by recording the need of transfusion within four 
weeks after completing radiotherapy treatment. In our study, 15 patients did not require transfusion; however, half of this non-transfusion 
group died within a month; therefore the radiotherapy treatment was not considered effective. For the ‘transfusion group’ (n = 29), which 
comprised patients receiving transfusion within four weeks after radiotherapy, nearly half of them (13 of 29) required only one transfusion 
before they died. The rest required multiple transfusions and three patients of this group required transfusion on more than five occasions, 
so it is evident that the survival of these patients was prolonged by the transfusion treatment, but initial haemostasis was achieved by 
radiotherapy. It is notable that in a group perceived to have a dire outlook, almost one in seven patients were alive one year after completing 
radiotherapy, and it may be that this simple treatment provides excellent palliation at small cost to the individual.
To date, there are no accurate measurable parameters to evaluate the effectiveness of radiotherapy for gastric cancer bleeding. Theoreti-
cally,	haemostatic	effects	can	be	accurately	assessed	by	direct	view	of	the	bleeding	source	through	an	endoscopic	approach	in	conjunction	
with examination of the haemoglobin level at regular intervals. However, this approach is not suitable or particularly helpful in patients who 
have advanced disease. In our retrospective study, the change in mean haemoglobin and also the requirement of transfusion were used 
as surrogates to assess efficacy of treatment.
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In conclusion, our study suggests that radiotherapy is a good option for patients with gastric cancer bleeding as shown by the overall 
median survival and the improvement of mean haemoglobin levels after radiotherapy. Either a single 8 Gy fraction or 20 Gy in five fractions, 
corresponding to a BED of 14.4to 28 Gy, appears to provide similar response rates to those treatments of higher BED (Table 4). Further 
investigations with control group not receiving radiotherapy for palliation of gastric cancer bleeding and larger sample size would provide 
more evidence of the efficacy of this treatment in controlling symptomatic bleeding, and as in most palliative treatments, it would be impor-
tant to assess the effect of treatment on quality of life, although such data are difficult to collect from patients who are frail and unfit.
RT: radiotherapy; CRT: chemoradiation; Hb: haemoglobin; 2D: two dimensional; 3D: three dimensional; CT: computed tomography; BED: 
biological effective dose; PA: posterior-anterior; L: lateral
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